The Clock Foundation is making epigenetic aging clocks more accessible for use in preclinical and clinical studies.
The Epigenetic Clock Development Foundation (” Clock Foundation“), a UCLA spin-out non-profit, is working to speed up the availability of treatments that extend life expectancy and health. Our focus is on adaptive clinical trials and epigenetic aging clocks. We will develop and identify key enabling technologies, identify promising teams, and make them available for our partners including researchers, physicians/clinics and drug development companies.
The epigenetic aging clocks are powerful indicators of biological age. Their reversal promises to lower the risk for multiple chronic diseases as well as to maintain the immune system. Preclinical and human studies have shown that epigenetic clocks can be used as a surrogate endpoint in anti-aging clinical trials.
We want to lower the cost of epigenetic testing and to do mechanistic studies. In addition, we will develop more powerful biomarkers for predicting lifespan and health span (including a fast, safe, and effective testing program for humans, model organisms, companion animals, and other pets). We will test and analyze several biomarkers of ageing, including markers of immunosenescence and epigenetic aging clocks. The work will lead to the qualification of several biomarkers for aging as surrogate trial ends.
Through our partners and collaborators we are currently conducting proof-of-concept studies on aging. We plan to create efficient, large-scale preclinical/clinical trial infrastructure in the U.S. as well as internationally. Our team has extensive experience in healthcare and life sciences, as well as deep knowledge in clinical translation and basic research. This team includes members of the TRIIM trial research group, which was a recent study that showed the reversal in epigenetic aging and other key aspects of immunosenescence among healthy older men between 50-65.
Why Us? Why now?
The past ten years of research by Dr. Steve Horvath has led to a revolution in aging science. This was possible thanks to the collaboration of data from hundreds clinical studies and tens upon thousands of patients. This unprecedented level of data sharing and accessibility of digital data was not possible 15 years ago. Our team proved that human epigenetic ageing could be reversed by using a combination FDA-approved drugs. This groundbreaking study demonstrated the importance of a non-profit infrastructure to rigorously assess and develop promising anti-aging therapies. We believe that, despite the public’s interest in longevity medicine and venture capital investment at an early stage, there is a lack of clear regulatory guidance and incentives that are hindering its development. These challenges will continue to impede the development of effective, affordable and safe preventive medicine that targets the biology of aging.
The Impact and Our Massively Transformative Purpose
Our goal is to make it possible for everyone to escape the slow aging process using affordable and safe interventions. This is possible by making epigenetic clock technology more accessible and ensuring its consistent use in clinical and preclinical research. Partly, we will follow the FDA’s approach, which helps ensure that new treatments are safe and effective. However, we will also help to craft and establish their approach for approving preventive medicine by regulatory development work on epigenetic age clocks. Our foundation is focused on continuing to achieve remarkable clinical and preclinical trials results. However, we have a deeper, longer-term and more comprehensive approach. This includes acquiring an in-depth understanding of the biology and mechanisms of aging, particularly with the new powerful “lens”, epigenetic ageing and epigenetic clocks. This is an element we consider essential that forms the foundation of our goals.